PRA signals shift towards innovative, long-term capital structures for UK life insurers

The Prudential Regulation Authority has signalled a shift in its stance on capital innovation for the UK life insurance sector, setting out a framework intended to broaden insurers’ access to “patient, long-term” capital while guarding against the systemic and prudential risks that have accompanied the growth of funded reinsurance.

According to the PRA’s November 2025 discussion paper, the regulator’s interest is driven by persistent constraints on traditional sources of capital for life insurers, including the high cost and limited appetite for public equity. Industry appetite for private capital, reinsurance and capital-light models has grown as a result. The PRA frames alternative life capital structures as a means to attract investors willing to align with the long duration of life liabilities, defer immediate returns, reinvest in productive UK assets and provide smoother returns that could free up insurer capital and capacity.

The paper sets out six high-level principles any proposed structure should meet. These include that alternative structures must not reduce the quality or quantity of capital supporting insurance risks; risk transfers to capital markets should be “contractually bounded and time-limited”; insurers must manage tail and residual risks; the primary effect should be capital relief rather than balance-sheet financing; insurers should retain a material portion of risk; and insurers must maintain control over core business operations. The PRA’s framing and language echo commentary in law‑firm analyses and industry briefings, which also emphasise the need to limit basis risk and avoid regulatory arbitrage. Industry participants were given until 6 February 2026 to respond, although the PRA and market observers expect consultation to continue beyond that date.

The regulator’s focus is explicitly informed by its longstanding scrutiny of funded reinsurance (FundedRe) and the bulk purchase annuities market. The PRA has repeatedly expressed concern about the systemic use and structural complexity of FundedRe arrangements, and in a September 2025 speech foreshadowed a desire to “unbundle” the asset/investment and longevity components of such transactions and to apply tighter regulatory treatment to the asset leg. Commentary from legal and consultancy firms has noted that the PRA’s alternative-capital work is intended in part to offer more targeted, transparent structures that address those concerns.

To illustrate possible routes to market, the discussion paper explores three case-study structures adapted from insurance and banking practice: an insurance special purpose vehicle (ISPV), a sidecar and a significant risk transfer (SRT)-style funded structure. The ISPV route draws on the United Kingdom’s existing Risk Transfer Regulations 2017 framework, under which risk transformation vehicles have historically been used to place general insurance catastrophe risks with capital markets. The PRA notes important differences between general insurance and life liabilities, for example, annuity books typically comprise existing, open-ended liabilities with uncertain maxima and pre-existing premium-derived capital, so direct replication of catastrophe-type ISPVs will not be straightforward.

Sidecars, by contrast, are presented as vehicles to raise third-party, often long-term equity to support life and annuity liabilities on a flow basis. These structures are commonly used in other jurisdictions and are typically designed to provide longer-duration capital aligned with annuity cashflows. An SRT-inspired model borrows from banking practice for transferring credit risk on loan portfolios; the PRA’s inclusion of SRT reflects its interest in separating longevity risk from associated asset exposures and in treating the asset leg with greater regulatory scrutiny, potentially characterising it as a loan-like exposure in some cases.

Across the case studies the PRA emphasises several calibrations likely to be critical to regulatory acceptance: clearly time‑bounded risk tranches rather than open-ended exposures; robust mechanisms to manage basis, tail and residual risks; limits on the proportion of an insurer’s balance sheet that can be ceded to third-party capital; and arrangements that preserve the insurer’s governance and investment control. The PRA also contemplates practical market issues such as investor exit, collateral mixes, coupon and principal mechanics and possible regulatory capital “grace periods” to manage transition between investors.

Regulatory treatment is a central theme. The PRA asks whether and how a life insurer might benefit from matching adjustment treatment in respect of assets with an ISPV or equivalent, whether an ISPV itself might be eligible for matching adjustment on deposited assets, and how regulatory capital credit should be given for non‑reinsurance protection such as guarantees or derivatives. The discussion paper also raises the potential role of ratings, collateral and syndication in determining the extent of regulatory credit, reflecting industry commentary that investor identity and financial strength will be decisive.

Tax and competitiveness are also raised as practical considerations. The PRA asks stakeholders to consider the United Kingdom’s attractiveness relative to incumbent offshore domiciles for insurance‑linked structures such as Bermuda‑style vehicles and whether technical amendments to the Risk Transformation (Tax) Regulations 2017 are needed to clarify domestic tax treatment for ISPVs.

Industry analysis and prior PRA work provide context to the discussion paper. Law‑firm briefings published since the PRA’s earlier consultations on FundedRe have charted the regulator’s heightened expectations on risk management, risk transfer and capital modelling for funded arrangements. Consultancies and advisers have highlighted use cases for alternative capital that extend beyond simple balance‑sheet relief, patient capital could support product development, deployment of higher‑yielding productive assets, management of credit‑concentration risk and support for annuity transactions, so long as prudential safeguards are preserved.

The PRA’s discussion paper is deliberately conceptual and framed to solicit industry responses. Its principles aim to allow innovation while making clear the regulator’s red lines: capital quality cannot be diluted, risk transfers must be finite and measurable, insurers must retain sufficient skin in the game and must keep operational control. Those conditions, together with detailed questions on capital treatment, tax and market mechanics, signal that any viable alternative‑capital market will require careful legal, accounting and regulatory design and likely new market infrastructure for investor exit and secondary trading.

Market participants and advisers will now seek to translate the PRA’s principles into implementable structures that can attract the “patient” capital the regulator describes without eroding policyholder protection or creating new channels for regulatory arbitrage. According to the PRA’s timetable, formal responses were due on 6 February 2026, but the paper’s breadth suggests prolonged engagement between regulators, insurers, investors, tax authorities and market infrastructure providers will follow before any material shift in market practice is realised.